Literature DB >> 23114631

What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture?

Bérengère Aubry-Rozier1, Delphine Stoll, Marc-Antoine Krieg, Olivier Lamy, Didier Hans.   

Abstract

Osteoporotic fracture (OF) is one of the major causes of morbidity and mortality in industrialized countries. Switzerland is among the countries with the greatest risk. Our aim was (1) to calculate the FRAX(®) in a selected Swiss population the day before the occurrence of an OF and (2) to compare the results with the proposed Swiss FRAX(®) thresholds. The Swiss Association Against Osteoporosis proposed guidelines for the treatment of osteoporosis based on age-dependent thresholds. To identify a population at a very high risk of osteoporotic fracture, we included all consecutive patients in the active OF pathway cohort from the Lausanne University Hospital, Switzerland. FRAX(®) was calculated with the available data the day before the actual OF. People with a FRAX(®) body mass index (BMI) or a FRAX(®) (bone mineral density) BMD lower than the Swiss thresholds were not considered at high risk. Two-hundred thirty-seven patients were included with a mean age of 77.2 years, and 80 % were female. Major types of fracture included hip (58 %) and proximal humerus (25 %) fractures. Mean FRAX(®) BMI values were 28.0, 10.0, 13.0, 26.0, and 37.0 % for age groups 50-59, 60-69, 70-79, and 80-89 years old, respectively. Fifty percent of the population was not considered at high risk by the FRAX(®) BMI. FRAX(®) BMD was available for 95 patients, and 45 % had a T score < -2.5 standard deviation. Only 30 % of patients with a normal or osteopenic BMD were classified at high risk by FRAX(®) BMD. The current proposed Swiss thresholds were not able to classify at high risk in 50 to 70 % of the studied population the day before a major OF.

Entities:  

Mesh:

Year:  2012        PMID: 23114631     DOI: 10.1007/s10067-012-2106-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

Review 1.  Development and use of FRAX in osteoporosis.

Authors:  J A Kanis; E V McCloskey; H Johansson; A Oden; O Ström; F Borgström
Journal:  Osteoporos Int       Date:  2010-05-13       Impact factor: 4.507

2.  Prediction of hip fracture risk by quantitative ultrasound in more than 7000 Swiss women > or =70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study.

Authors:  Marc-Antoine Krieg; Jacques Cornuz; Christiane Ruffieux; Guy Van Melle; Daniel Büche; Maximilian A Dambacher; Didier Hans; Florian Hartl; Hansjorg J Häuselmann; Marius Kraenzlin; Kurt Lippuner; Maurus Neff; Pierro Pancaldi; Rene Rizzoli; Franco Tanzi; Robert Theiler; Alan Tyndall; Claus Wimpfheimer; Peter Burckhardt
Journal:  J Bone Miner Res       Date:  2006-09       Impact factor: 6.741

3.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

Review 4.  Pitfalls in the external validation of FRAX.

Authors:  J A Kanis; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2011-11-26       Impact factor: 4.507

5.  Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.

Authors:  L-A Fraser; L Langsetmo; C Berger; G Ioannidis; D Goltzman; J D Adachi; A Papaioannou; R Josse; C S Kovacs; W P Olszynski; T Towheed; D A Hanley; S M Kaiser; J Prior; S Jamal; N Kreiger; J P Brown; H Johansson; A Oden; E McCloskey; J A Kanis; W D Leslie
Journal:  Osteoporos Int       Date:  2010-12-16       Impact factor: 4.507

6.  Management of fragility fractures in Switzerland: results of a nationwide survey.

Authors:  Norbert Suhm; Olivia Lamy; Kurt Lippuner
Journal:  Swiss Med Wkly       Date:  2008-11-15       Impact factor: 2.193

7.  FRAX assessment of osteoporotic fracture probability in Switzerland.

Authors:  K Lippuner; H Johansson; J A Kanis; R Rizzoli
Journal:  Osteoporos Int       Date:  2009-06-11       Impact factor: 4.507

8.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

Review 9.  How to decide who to treat.

Authors:  J A Kanis; E V McCloskey; H Johansson; O Strom; F Borgstrom; A Oden
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-12       Impact factor: 4.098

10.  Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women.

Authors:  K Lippuner; H Johansson; J A Kanis; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-10-31       Impact factor: 4.507

View more
  6 in total

Review 1.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

2.  Comparison between real-world practice and application of the FRAX algorithm in the treatment of osteoporosis.

Authors:  Francesca Zoccarato; Chiara Ceolin; Caterina Trevisan; Anna Citron; Labjona Haxhiaj; Aurelio Guarnaccia; Matteo Panozzo; Carlotta Campodall'Orto; Alessandra Coin; Sandro Giannini; Giuseppe Sergi
Journal:  Aging Clin Exp Res       Date:  2022-08-16       Impact factor: 4.481

3.  Were you identified to be at high fracture risk by FRAX® before your osteoporotic fracture occurred?

Authors:  Xiao-feng Chen; Xiao-lin Li; Hui Zhang; Ge-jun Liu
Journal:  Clin Rheumatol       Date:  2014-02-28       Impact factor: 2.980

4.  Failure in the application of fragility fracture prevention guidelines.

Authors:  M H Elvey; H Pugh; G Schaller; G Dhotar; B Patel; M J Oddy
Journal:  Ann R Coll Surg Engl       Date:  2014-07       Impact factor: 1.891

5.  Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey.

Authors:  Nese Olmez Sarikaya; Secil Kapar Yavasi; Gulten Tan; Servet Satiroglu; Arife Hilal Yildiz; Bengi Oz; Ozlem Yoleri; Asuman Memis
Journal:  Clin Rheumatol       Date:  2014-01-29       Impact factor: 2.980

Review 6.  Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.

Authors:  Joanna E M Sale; Matthew Gray; Daniel Mancuso; Taucha Inrig; Gilles Boire; Marie-Claude Beaulieu; Larry Funnell; Earl Bogoch
Journal:  Rheumatol Int       Date:  2018-10-26       Impact factor: 2.631

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.